Patent ID: 11932643
Assignee: NAVIRE PHARMA, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A compound of structural Formula I, or a salt or tautomer thereof, wherein:
a is 0 or 1;
b is 0 or 1;
R1a is selected from the group consisting of halo, C6-10aryl, C3-8cycloalkyl, C3-8cycloalkenyl, and a 5-9 membered heteroaryl group containing 1 to 4 heteroatoms or groups independently selected from the group consisting of N, C(O), 0, and S; said aryl or heteroaryl of R1a is unsubstituted or substituted with 1 to 5 R12 groups independently selected from the group consisting of halo, hydroxy, amino, C1-4alkylamino, C1-4dialkylamino, cyano, C1-4alkyl, C1-4alkoxy, C1-4hydroxyalkyl, C1-4dihydroxyalkyl, hydroxyC1-4alkoxy, dihydroxyC1-4alkoxy, C1-4haloalkyl, C1-4aminoalkyl, C3-8cycloalkyl, C3-8cycloalkenyl, NR15C(O)R13, NR15C(O)OR13, NR13C(O)NR15R16, NR15S(O)R13, NR15S(O)2R13, C(O)NR15R16, S(O)NR15R16, S(O)2NR15R16, C(O)R13, C(O)OR13, OR13, SR13, S(O)R13, and S(O)2R13;
R1b is selected from the group consisting of cyano, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 dihydroxyalkyl, —CF2OH, —CHFOH, —NH—NHR19, —NH—OR19, —O—NR19R20, —NHR19, —OR19, —NHC(O)R19, —NHC(O)NHR19, —NHS(O)2NHR19, —NHS(O)2R19, —C(O)OR19, —C(O)NR19R20, —C(O)NH(CH2)nOH, —C(O)NH(CH2)nR21, —C(O)R21, —NH2, —OH, —S(O)2NR19R20, C3-C8 cycloalkyl, aryl, heterocyclyl having 1-5 heteroatom ring vertices selected from the group consisting of N, O, S and P, and heteroaryl having 1-5 heteroatom ring vertices selected from the group consisting of N, O, S and P; wherein the subscript n is an integer of from 0 to 6; and wherein the aryl, heteroaryl, heterocyclyl, and cycloalkyl are each unsubstituted or substituted with 1 to 3 members independently selected from the group consisting of C1-4 alkyl, —OH, —NH2, —OR21, halogen, cyano and oxo;
R2, R3, R10, and R11 are each independently selected from the group consisting of hydrogen, C1-4alkyl, and C3-8cycloalkyl;
R4, R5, R8, and R9 are independently selected from the group consisting of hydrogen, cyano, C1-4alkyl, C1-4alkoxy, amino, hydroxy, C3-8cycloalkyl, halo, and C1-4alkylamino;
R6 and R7 together with the carbon atom to which they are both attached form a 3- to 7-membered saturated or unsaturated ring that can contain 1 to 3 heteroatoms or groups independently selected from the group consisting of N, C(O), O, and S(O)m, and that is unsubstituted or substituted with one R17 group, and that is unsubstituted or substituted with one or more R18 groups;
m is 0, 1, or 2;
any two groups of R2, R3, R4, R5, R8, R9, R10 and R11 can form a 5- to 6-membered ring, optionally containing a N, O or S heteroatom;
any two groups of R2, R4, R8 and R10 can form a direct bond, or a 1 or 2 atom carbon bridge;
R13, R15, and R16 are independently selected from the group consisting of hydrogen, C1-4alkyl, C3-8cycloakyl, and 3- to 6-membered heterocyclyl, wherein said alkyl, cycloalkyl, and 3- to 6-membered heterocyclyl are each unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, cyano and halo;
each R17 and R18 is independently selected from the group consisting of amino, halo, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, C1-4alkyl, and C1-4alkoxy;
each R19 and R20 is independently selected from the group consisting of H, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6cycloalkyl; and
each R21 is independently selected from the group consisting of H, —OH, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl and C3-6cycloalkyl.